SAB Biotherapeutics (NASDAQ:SABS) Price Target Raised to $12.00 at Leerink Partners

by · The Cerbat Gem

SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) had its price objective upped by equities research analysts at Leerink Partners from $7.00 to $12.00 in a report issued on Monday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Leerink Partners’ price target indicates a potential upside of 260.36% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of SAB Biotherapeutics in a research report on Monday. Jefferies Financial Group began coverage on SAB Biotherapeutics in a research report on Wednesday, May 20th. They set a “buy” rating and a $11.00 price target on the stock. Zacks Research upgraded SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th. Rodman & Renshaw restated a “buy” rating and set a $13.00 price target on shares of SAB Biotherapeutics in a research report on Monday, May 11th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of SAB Biotherapeutics in a research report on Friday, April 10th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $11.63.

View Our Latest Stock Analysis on SABS

SAB Biotherapeutics Stock Performance

Shares of SABS opened at $3.33 on Monday. The firm’s 50 day simple moving average is $3.70 and its 200 day simple moving average is $3.85. The company has a market capitalization of $254.63 million, a P/E ratio of -1.58 and a beta of 0.54. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.45 and a quick ratio of 11.45. SAB Biotherapeutics has a 1-year low of $1.60 and a 1-year high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). Sell-side analysts forecast that SAB Biotherapeutics will post -1.19 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SAB Biotherapeutics

A number of hedge funds have recently made changes to their positions in the business. Seven Fleet Capital Management LP bought a new stake in shares of SAB Biotherapeutics in the 1st quarter worth approximately $1,915,000. DV Trading LLC bought a new stake in shares of SAB Biotherapeutics in the 1st quarter worth approximately $1,532,000. Perceptive Advisors LLC lifted its holdings in shares of SAB Biotherapeutics by 700.8% in the 1st quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company’s stock worth $24,634,000 after acquiring an additional 5,628,533 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of SAB Biotherapeutics by 424.8% in the 1st quarter. Bank of America Corp DE now owns 55,697 shares of the company’s stock worth $213,000 after acquiring an additional 45,084 shares during the last quarter. Finally, Stempoint Capital LP lifted its holdings in shares of SAB Biotherapeutics by 155.9% in the 1st quarter. Stempoint Capital LP now owns 375,000 shares of the company’s stock worth $1,436,000 after acquiring an additional 228,442 shares during the last quarter. 7.82% of the stock is currently owned by institutional investors.

SAB Biotherapeutics Company Profile

(Get Free Report)

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.

Featured Articles